Teaming up to exceed expectations
Our team is passionate about discovering new drug lead compounds for our partners with the potential to cure diseases, and bringing innovation in healthcare. With our experience and expertise in drug discovery, we help our clients build the future of patient-centric healthcare.
Dr. Kai Lamottke | Managing Director
Kai Lamottke is co-founder of Bicoll GmbH, Munich where he holds a position as Managing Director. Since 2001 he is also appointed as General Manager and member of the Board of Directors of Bicoll Biotechnology (Shanghai) Co. Ltd.
Maria Lamottke, Ph.D. | ChairWOman of the Board of Directors
Maria Lamottke joined Bicoll GmbH, Munich and Bicoll Biotechnology (Shanghai) Co. Ltd. in December 2010. In 2015 she has taken over the position of the Head of Business Affairs & IR. Since January 2016 she is appointed as Chairwoman of the Board of Directors of Bicoll Biotechnology (Shanghai) Co. Ltd.
Prof. Dr. Yang Ye | Vice Chairman of Board of Directors
Yang Ye is co-founder of Bicoll GmbH, Munich. In 2001 he was appointed Vice Chairman of the Board of Directors for Bicoll Biotechnology (Shanghai) Co. Ltd. Dr. Ye also holds a position as professor of State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences. As a member of Bicoll’s Board of Directors in Shanghai he provides input in special academia related topics.
Valuable outside view in research and business
Prof. Dr. Thorsten Bach | Professor of Organic Chemistry, Technical University of Munich, Germany
Prof. Bach became full professor at the Technical University of Munich in 2000. He is specialized in catalysis, photochemistry and organometallic chemistry. A particular focus in his group lays on the total synthesis of bioactive natural products. Professor Bach authored nearly 200 publications and patents so far. His work was awarded by several renowned research prices, e.g. AstraZeneca Research Award, Novartis European Young Investigator Award, Degussa Award for Chirality in Chemistry 2006. Since 2006 he his elected Member of the German Academy of Sciences, Leopoldina (Halle, Saale). In 2020 he got recognition with Gottfried Wilhelm Leibniz Award.
Prof. K. Peter C. Vollhardt | Professor of Chemistry, University of California at Berkeley USA
Dr. Peter C. Vollhardt is Professor at the Department of Chemistry, University of California at Berkeley, Senior Principal Investigator at the Chemical Science Division, Lawrence Berkeley National Laboratory, and Assistant Dean to the College of Chemistry. As one of the world’s foremost organic chemists, he received many renowned, outstanding scientific awards.
Professor Vollhardt has more than 35 years of experience in the application of transition metals to enable the synthesis of complex natural and unnatural products. His outstanding scientific work led to over 265 scientific papers. In addition he authored the standard college textbook on organic chemistry and serves as Chief Editor for the journal Synlett.
Hardy Debuch, PhD | Founder and Head of DHD Management Consulting AG, Germany
Hardy Debuch has more than 30 years of experience in the pharmaceutical industry. He assumed leading positions in research and marketing with E. Merck, Darmstadt/Germany and Röhm Pharma, Germany before he joined Schwarz Pharma, Germany in 1983. As a Board member, he was responsible to change Schwarz Pharma from a German-oriented company to a global market player. In 1995, Hardy Debuch founded his own consulting company DHD Management Consulting AG. His clients are, beside German pharmaceutical companies, mainly Japanese and US companies.
Michael Bogenstaetter, PhD | Vice President, Strategy & Corporate Development MDS Inc., Toronto Canada
Michael Bogenstaetter has over 15 years experience in biopharmaceutical research and life science management & strategy. Since 2008, Michael is VP of Strategy & Corporate Development at MDS Inc, driving strategic acquisitions and divestitures. Before he advised leading multinational pharma & biopharma companies on key strategic and operational issues as a Project Leader and member of the Health Care practice of The Boston Consulting Group (Boston office). Prior, Michael was an Associate Director at Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA and medicinal chemist with Johnson & Johnson Pharmaceutical Research & Development in La Jolla, CA.